Sehouli J - Search Results

1

Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study.

Prieske K, Woelber L, Muallem MZ, Eulenburg C, Jueckstock JK, Hilpert F, de Gregorio N, Iborra S, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann K, Beckmann M, Mustea A, Meier W, Harter P, Wimberger P, Sehouli J, Mahner S. Prieske K, et al. Among authors: sehouli j. Gynecol Oncol. 2021 May;161(2):442-448. doi: 10.1016/j.ygyno.2021.02.025. Epub 2021 Feb 26. Gynecol Oncol. 2021. PMID: 33648748

2

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.

Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W; Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Gynecol Oncol. 2002 May;85(2):321-6. doi: 10.1006/gyno.2002.6623. Gynecol Oncol. 2002. PMID: 11972395 Clinical Trial.

3

Interleukin-1 receptor antagonist gene polymorphism and cancer.

Sehouli J, Mustea A. Sehouli J, et al. Clin Infect Dis. 2002 Jun 1;34(11):1535-6. doi: 10.1086/340530. Clin Infect Dis. 2002. PMID: 12015703 No abstract available.

4

Polymorphism of IL-1 receptor antagonist gene: role in cancer.

Sehouli J, Mustea A, Könsgen D, Katsares I, Lichtenegger W. Sehouli J, et al. Anticancer Res. 2002 Nov-Dec;22(6A):3421-4. Anticancer Res. 2002. PMID: 12530098 Review.

5

Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer.

Mustea A, Sehouli J, Könsgen D, Stengel D, Sofroni D, Lichtenegger W. Mustea A, et al. Among authors: sehouli j. Anticancer Res. 2003 Mar-Apr;23(2A):1099-102. Anticancer Res. 2003. PMID: 12820354

6

Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.

Sehouli J, Akdogan Z, Heinze T, Könsgen D, Stengel D, Mustea A, Lichtenegger W. Sehouli J, et al. Anticancer Res. 2003 Mar-Apr;23(2A):1115-8. Anticancer Res. 2003. PMID: 12820357

7

["IMO"--intraoperative mapping of ovarian cancer].

Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W. Sehouli J, et al. Zentralbl Gynakol. 2003 Mar-Apr;125(3-4):129-35. doi: 10.1055/s-2003-41864. Zentralbl Gynakol. 2003. PMID: 12961105 German.

8

Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer.

Sehouli J, Mustea A, Koensgen D, Chen FC, Lichtenegger W. Sehouli J, et al. Ann Oncol. 2003 Oct;14(10):1501-4. doi: 10.1093/annonc/mdg413. Ann Oncol. 2003. PMID: 14504049 Free article.

9

Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer.

Sehouli J, Mustea A, Koensgen D, Lichtenegger W. Sehouli J, et al. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1205-8. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14652282

10

Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies.

Sehouli J, Könsgen D, Nimpsch R, Stengel D, Oskay G, Mustea A, Oertel J, Lichtenegger W. Sehouli J, et al. Anticancer Res. 2003 Sep-Oct;23(5b):4133-40. Anticancer Res. 2003. PMID: 14666614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

766 results

Search Page